Skip to main content
. Author manuscript; available in PMC: 2019 Sep 17.
Published in final edited form as: Exp Cell Res. 2016 Jun 2;345(2):255. doi: 10.1016/j.yexcr.2016.05.021

Table 1.

Significant relative levels of mRNA, protein and phosphorylated protein following three days of treatment with Raloxifene and/or PX-866.

Micromolar treatment TERT p21 Cyc D1 Axin2 LIF HB EGF DEC1
Control 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.0 Raloxifene 0.328* 0.158* 0.338*
0.4 PX-866
Raloxifene+0.1 PX-866 0.396* 0.398* 0.260* 0.283* 0.370*
Raloxifene+0.4 PX-866 0.539* 0.336*
Raloxifene+0.8 PX-866 2.76* 0.356* 1.95*
Micromolar treatment pMDM2 protein
Control 1.0
1.0 Raloxifene
0.4 PX-866 0.379*
Raloxifene +0.1 PX-866 0.395*
Raloxifene +0.4 PX-866 0.385*
Raloxifene +0.8 PX-866 0.353*
*

p<0.05.